1. Home
  2. STTK vs IROQ Comparison

STTK vs IROQ Comparison

Compare STTK & IROQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • IROQ
  • Stock Information
  • Founded
  • STTK 2016
  • IROQ 1883
  • Country
  • STTK United States
  • IROQ United States
  • Employees
  • STTK N/A
  • IROQ N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • IROQ Savings Institutions
  • Sector
  • STTK Health Care
  • IROQ Finance
  • Exchange
  • STTK Nasdaq
  • IROQ Nasdaq
  • Market Cap
  • STTK 83.8M
  • IROQ 82.7M
  • IPO Year
  • STTK 2020
  • IROQ 2011
  • Fundamental
  • Price
  • STTK $2.14
  • IROQ $25.56
  • Analyst Decision
  • STTK Hold
  • IROQ
  • Analyst Count
  • STTK 6
  • IROQ 0
  • Target Price
  • STTK $2.67
  • IROQ N/A
  • AVG Volume (30 Days)
  • STTK 1.5M
  • IROQ 1.5K
  • Earning Date
  • STTK 11-13-2025
  • IROQ 11-03-2025
  • Dividend Yield
  • STTK N/A
  • IROQ 1.56%
  • EPS Growth
  • STTK N/A
  • IROQ 139.63
  • EPS
  • STTK N/A
  • IROQ 1.37
  • Revenue
  • STTK $2,997,000.00
  • IROQ $26,459,000.00
  • Revenue This Year
  • STTK N/A
  • IROQ N/A
  • Revenue Next Year
  • STTK N/A
  • IROQ N/A
  • P/E Ratio
  • STTK N/A
  • IROQ $18.74
  • Revenue Growth
  • STTK N/A
  • IROQ 19.82
  • 52 Week Low
  • STTK $0.69
  • IROQ $18.36
  • 52 Week High
  • STTK $3.95
  • IROQ $25.97
  • Technical
  • Relative Strength Index (RSI)
  • STTK 58.93
  • IROQ 61.20
  • Support Level
  • STTK N/A
  • IROQ $25.50
  • Resistance Level
  • STTK $2.01
  • IROQ $25.63
  • Average True Range (ATR)
  • STTK 0.21
  • IROQ 0.19
  • MACD
  • STTK 0.01
  • IROQ 0.01
  • Stochastic Oscillator
  • STTK 99.53
  • IROQ 89.45

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About IROQ IF Bancorp Inc.

IF Bancorp Inc is a holding company mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company, in association, takes deposits from the general public and invests those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, etc., and offers a variety of deposit accounts and alternative delivery channels. In addition to the traditional banking products and services, the group also offers a full line of property and casualty insurance products, annuities, mutual funds, individual securities, managed accounts, and other financial services.

Share on Social Networks: